Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

E 2814

Next Previous
X
Search
Drug Profile

E 2814

Alternative Names: E-2814

Latest Information Update: 01 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd; University College London
  • Developer Eisai Co Ltd
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease

Most Recent Events

  • 24 May 2024 Eisai completes a phase-I/II trial in Alzheimer's disease in the USA and the UK (IV, Infusion) (NCT04971733) (EudraCT2020-005728-12)
  • 16 Jul 2023 Adverse event, pharmacokinetics, pharmacodynamics, immunogenicity data from a phase I trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2023 (AAIC-2023)
  • 16 Jul 2023 Pooled analysis adverse event, pharmacokinetics and pharmacodynamics, from a phase-I and phase-I/II trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top